Radiopharmaceuticals Market: Growing Demand for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Radiopharmaceuticals Market: Growing Demand for Radiopharmaceuticals for Cancer Treatment to Boost Market Expansion at 18.30% CAGR: Transparency Market Research

Albany, NY, Dec. 11, 2015 (GLOBE NEWSWIRE) -- According to a recent market research report released by Transparency Market Research, the global radiopharmaceuticals market is estimated to witness rapid expansion at a CAGR of 18.30% during the period between 2012 and 2018. The report, titled " Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018 ", projects the global radiopharmaceuticals market to reach a valuation of US$12.2 bn by 2018. The overall market was worth US$3.8 bn in 2011.

Browse the full Radiopharmaceuticals Market (Generators, PET & SPECT radioiosotopes, Technetium-99m, Gallium-67, Iodine-123, 18F-FDG, Rubidium-82, Yttrium-90 and others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018 report at http://www.transparencymarketresearch.com/rad...arket.html

The report points out that the growing preference for disease-specific therapy, especially radiopharmaceutical-based cancer therapy, will boost the global radiopharmaceuticals market. Increasing awareness about accurate diagnosis, coupled with expanding molecular imaging applications, will push the growth of the market during the forecast horizon. However, the report mentions that strict regulatory guidelines for production, storage, and usage of radiopharmaceuticals will hamper the growth of the global radiopharmaceuticals market. Worldwide supply shortages, along with price sensitivity and the presence of competitive alternatives, will also negatively impact the overall market. The report states that the increasing demand for accurate diagnosis and treatment, particularly in emerging markets, and the rise of radiopharmaceutical-based personalized therapy will create new growth opportunities for the global radiopharmaceuticals market.

Get Sample Report Copy of Radiopharmaceuticals Market: http://www.transparencymarketresearch.com/sam...rep_id=213

On the basis of type of radioactive isotope, the report segments the global radiopharmaceuticals market into Mo-99/Tc-99m generators, Sr-82/Rb-82 generators, Ge-68/Ga-67,68 generators,  W-188/Re-188 generators, and Sr-90/Y-90 generators. So far, Mo-99/Tc-99m generators have dominated the overall market owing to their established marketing channels. However, during the forecast horizon, it is expected that other segments of the market will witness growth at double-digit CAGRs.

Depending on application, the report categorizes the global radiopharmaceuticals market into diagnosis and therapy. The usage of radiopharmaceuticals for diagnosis includes the techniques of SPECT and PET, wherein radiopharmaceuticals are applied for the diagnosis of cardiovascular disorders, cancer, neurological disorders, thyroid diseases, and gastrointestinal disorders. The usage of radiopharmaceuticals for therapy includes various isotopes used in oncology, neurology, and cardiology. Oncology dominates the overall market for radiopharmaceuticals. While treating cancer, these radioactive agents target the cancerous areas in the body to destroy the affected tissues.

Browse Press Release of Radiopharmaceuticals Market: http://www.transparencymarketresearch.com/pre...dustry.htm

Radiopharmaceuticals Market by Generator Types

  • Mo-99/Tc-99m generator
  • Sr-82/Rb-82 generator
  • Ge-68/Ga-68 generator
  • Sr-90/Y-90 generator
  • W-188/Re-188 generator

Radiopharmaceuticals Market by End-Users

  • Hospitals & Medical Centers
  • Diagnostic Centers

Radiopharmaceuticals Market by Applications

Diagnosis

Diagnosis by Technique

SPECT

  • Technetium (Tc-99m)
  • Thallium (TI-201)
  • Gallium (Ga-67)
  • Iodine (I-123)
  • Rhenium (Re-186)
  • Yttrium (Y-90)
  • Others

PET

  • Fludeoxyglucose (18F-FDG)
  • Rubidium (Rb-82)
  • Others (Carbon-11 choline, Nitrogen-13 ammonia)

Diagnosis by Indications

  • Oncology
  • Cardiovascular
  • Others (Neurological, Thyroid, Gastrointestinal)

Therapy

  • Systemic Oncology
  • Iodine (I-131)
  • Yttrium (90Y)
  • Samarium (Sm-153)
  • Strontium (89Sr)
  • Rhenium (186Re)
  • Lutetium (Lu-177)
  • Erbium (169Er)
  • Others

Others (Cardiology, Neurology)

Radiopharmaceuticals Market by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Other Reports by Transparency Market Research:

Nuclear Medicine/Radiopharmaceuticals Market: http://www.transparencymarketresearch.com/nuc...arket.html

Immunoprotein Diagnostic Testing Market Driven by Urgent Need for Preventive Healthcare in Emerging Economies: http://www.transparencymarketresearch.com/imm...sting.html

Medical Imaging Reagents Market to Reach US$18.5 Billion in 2019 owing to Rising Demand for Diagnostic Imaging Technologies: http://www.transparencymarketresearch.com/bio...arket.html

Single-Use Technologies for Biopharmaceuticals Market: http://www.transparencymarketresearch.com/sin...arket.html

About Us:

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Mr. Sudip.S 90 State Street, Suite 700 Albany, NY 12207 United States. Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com Blog: http://www.tmrblog.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Office Properties Income Trust Completes Debt Restructuring Deal

Updated Category News Views 214

Office Properties Income Trust Completes Debt Restructuring Today marks an important milestone for Office Properties Income Trust (NASDAQ: OPI). This national real estate investment trust, known for its focus on high-quality office properties, has recently completed a private exchange regarding its previously outlined 4.50% senior unsecured notes due 2025. This...

Continue Reading
Federal Reserve Vice Chair Barr Evaluates Legal Counsel Options

Updated Category News Views 103

Federal Reserve Vice Chair Barr Looks Into Legal Options In an intriguing twist in the political landscape, Federal Reserve Vice Chair for Supervision Michael Barr is reportedly assessing his legal options. This situation comes in light of possible moves from the incoming presidential administration to dispose of him from his position. This potential conflict has left...

Continue Reading
Understanding the Growth of Your Investment in XPO Over Time

Updated Category News Views 238

Understanding the Growth of Your Investment in XPO Over Time XPO (NYSE:XPO) has shown remarkable performance in the market over the last decade, outpacing average market returns. With an annualized return rate of 28.88%, XPO has achieved an impressive 16.34% better performance than the market average. Presently, the company's market capitalization stands at approximately...

Continue Reading
Certificate Hero Partners with Brown & Brown for Efficiency

Updated Category News Views 205

Certificate Hero and Brown & Brown Join Forces Certificate Hero recently announced a strategic partnership with Brown & Brown, a prominent leader in the insurance brokerage sector. This collaboration aims to transform the certificate of insurance (COI) issuance process by utilizing Certificate Hero’s state-of-the-art technology. Innovative Solutions for Certificate...

Continue Reading
ConocoPhillips Reports Strong Q3 Earnings with Optimistic Future

Updated Category News Views 207

ConocoPhillips Achieves Remarkable Third Quarter Performance Recently, ConocoPhillips has captivated investors with its impressive third-quarter results, leading to a notable adjustment in the stock's price target. The latest evaluation, conducted by Susquehanna, has raised the target for ConocoPhillips (NYSE: COP) to $148, an increase from the previous $144. This...

Continue Reading